Rapsgatan 7E
Uppsala
Sweden
46 1 87 80 88 00
https://www.orexo.com
Settore/i:
Settore:
Impiegati a tempo pieno: 116
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Nikolaj Sorensen | President & CEO | 5,84M | N/D | 1972 |
Mr. Fredrik Jarrsten | Executive VP & CFO | N/D | N/D | 1967 |
Ms. Cecilia Coupland | Senior VP & Head of Operations | N/D | N/D | 1976 |
Lena Wange | Investor Relations & Communications Director | N/D | N/D | N/D |
Mr. Robert Ronn | Senior VP and Head of R&D | N/D | N/D | 1976 |
Dr. Edward Kim M.B.A., M.D. | Chief Medical Officer | N/D | N/D | N/D |
Mr. Robert A. Deluca | President of Orexo US Inc | N/D | N/D | 1961 |
Mr. Jesper Lind | Advisor | N/D | N/D | 1960 |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
L'ISS Governance QualityScore di Orexo AB (publ) al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 1; diritti degli azionisti: 4; retribuzione: 10.